Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.38
-0.0300-1.24%
Post-market: 2.390.0100+0.42%19:47 EDT
Volume:4.10M
Turnover:9.74M
Market Cap:2.25B
PE:-4.86
High:2.44
Open:2.42
Low:2.33
Close:2.41
Loading ...

Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.10 a Share, vs. FactSet Est of $0.11 Loss

MT Newswires Live
·
05 Aug

ImmunityBio Inc. Reports 60% Revenue Increase in Q2 2025, Reduces Net Loss to $222.2 Million

Reuters
·
05 Aug

Immunitybio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code

THOMSON REUTERS
·
05 Aug

ImmunityBio Reports Q2 Preliminary Revenue

MT Newswires Live
·
25 Jul

ImmunityBio Announces $80 Million Equity Financing from Institutional Investors in Direct Offering

Reuters
·
25 Jul

Immunitybio, Inc. Announces Execution of $80 Million Equity Financing From Multiple Institutional Investors

THOMSON REUTERS
·
25 Jul

Immunitybio Inc - Warrants Could Add $96 Mln in Proceeds

THOMSON REUTERS
·
25 Jul

ImmunityBio Reports 60% Revenue Increase in Q2 2025, Totaling $26.4 Million, Driven by ANKTIVA Unit Growth

Reuters
·
25 Jul

Immunitybio Reports 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code With Regulatory Updates

THOMSON REUTERS
·
25 Jul

Immunitybio Inc - Q2 2025 Revenue $26.4 Mln

THOMSON REUTERS
·
25 Jul

Immunitybio Inc - UK Mhra Approves Marketing Authorization Application of Anktiva

THOMSON REUTERS
·
25 Jul

Los Angeles Times to go public, owner Soon-Shiong says

Reuters
·
22 Jul

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
08 Jul

UK MHRA Grants Marketing Authorization for ImmunityBio's ANKTIVA Plus BCG for Bladder Cancer Treatment

Reuters
·
08 Jul

BRIEF-UK's MHRA Approves Nogapendekin Alfa Inbakicept To Treat Patients With A Type Of Bladder Cancer

Reuters
·
04 Jul

ImmunityBio Inc. Conducted Annual Meeting of Stockholders

Reuters
·
21 Jun

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
03 Jun

ImmunityBio Inc. to Attend ASCO Annual Meeting 2025 in Chicago

Reuters
·
03 Jun

Unusually active option classes on open June 2nd

TIPRANKS
·
02 Jun

ImmunityBio Inc. Receives FDA Expanded Access Authorization for ANKTIVA Cancer BioShield™ to Treat Lymphopenia in Solid Tumor Patients

Reuters
·
02 Jun